升高的Metrnβ及其与疾病活动的关联在系统性红斑狼
Chen Zhang1,2, Shijie Cai3, Ying Li1
1Center of Clinical Laboratory Medicine, Zhongda Hospital, Southeast University, Nanjing 210009, China.
International journal of molecular sciences
|September 9, 2023
概括
梅特尼希-β (Metrnβ) 在全身性红斑狼 (SLE) 中升高,与疾病活性和免疫标志物相关. 这种细胞因子显示出作为早期SLE识别和预测免疫反应的生物标志物的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 生物化学 生物化学
背景情况:
- 系统性红斑狼 (SLE) 是一种复杂的自身免疫性疾病,其发病因子尚未完全理解.
- 一种新型细胞因子Metternich-beta (Metrnβ) 涉及炎症性疾病,但其在SLE中的具体作用尚不清楚.
研究的目的:
- 研究Metrnβ在SLE患者中的临床意义和诊断潜力.
- 探索Metrnβ水平与SLE疾病活性,免疫细胞种群和炎症标志物之间的关系.
主要方法:
- 在SLE患者和健康对照中量化循环中的Metrnβ水平.
- 对Metrnβ与临床指标,细胞因子/化学因子 (CXCL9,IL10,IL18,IL1RA) 和免疫细胞 (Treg,B10,ILC2) 的相关性分析.
- 接收器操作特征 (ROC) 曲线分析,以评估Metrnβ对SLE的诊断准确性.
主要成果:
- 在SLE患者中观察到显著升高的Metrnβ水平,特别是在活跃的疾病阶段.
- Metrnβ水平与SLE疾病活动指标和特定的炎症细胞因子 (CXCL9,IL10,IL18,IL1RA) 有积极的相关性.
- Metrnβ与调节性T细胞 (Treg),B10细胞呈反相关性,与第2组先天性淋巴细胞 (ILC2) 呈负相关性;ROC分析表明Metrnβ是潜在的生物标志物,AUC为0.8250.
结论:
- Metrnβ在SLE中显著上调,并且在免疫学上与疾病活性有关.
- Metrnβ可以作为一种有价值的生物标志物,用于早期检测和预测SLE的免疫反应.
- 对Metrnβ在SLE治疗潜力的进一步研究是有必要的.
相关概念视频
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
38
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38
Nephrotic Syndrome II : Assessment and Medical Management
8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8


